{"request_id":"a796b2c0cb70feb1bdb7217b8f48125b","results":{"ticker":"BIIB","name":"Biogen Inc. Common Stock","market":"stocks","locale":"us","primary_exchange":"XNAS","type":"CS","active":true,"currency_name":"usd","cik":"0000875045","composite_figi":"BBG000C17X76","share_class_figi":"BBG001S67826","market_cap":36272344376.96,"phone_number":"(781) 464-2000","address":{"address1":"225 BINNEY STREET","city":"CAMBRIDGE","state":"MA","postal_code":"02142"},"description":"Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.","sic_code":"2836","sic_description":"BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)","ticker_root":"BIIB","homepage_url":"https://www.biogen.com","total_employees":8725,"list_date":"1991-09-17","branding":{"logo_url":"https://api.polygon.io/v1/reference/company-branding/YmlvZ2VuLmNvbQ/images/2023-12-01_logo.svg","icon_url":"https://api.polygon.io/v1/reference/company-branding/YmlvZ2VuLmNvbQ/images/2023-12-01_icon.jpeg"},"share_class_shares_outstanding":144900000,"weighted_shares_outstanding":144898112,"round_lot":100},"status":"OK"}
